Anaemia Haematological Disorders Anaemia in chronic diseases classified elsewhere
Conditions
Interventions
The intervention was administration of HMR4396 at a dose of 150 U/kg or 300 U/kg compared to placebo. All study treatments were given three times weekly subcutaneously for 12 weeks.
Quality of life w
Sponsors
Hoechst Marion Roussel (Shire Pharmaceuticals) (France)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men or women, 18 years of age or older, with cancer except for acute leukaemias, malignancies of the myeloid cell line and myelodysplasia 2. Receiving cancer chemotherapy with at least two cycles remaining when randomised to study medication 3. Eastern Cooperative Oncology Group (ECOG) performance score of zero, one or two 4. Life expectancy of three months or greater 5. Haemoglobin (Hgb) less than or equal to 10.5 g/dL 6. Women were to be surgically sterile, post-menopausal (greater than one year) or using an effective method of birth control and were to have had a negative serum pregnancy test (quantitative human chorionic gonadotropin radioimmunoassay test) prior to study medication 7. Men had to agree to an effective method of contraception 8. Laboratory values within the following parameters: 8.1. Neutrophils greater than 500 cells/mm^3 (absolute value = 0.5 x 1000/mm^3 [as per Amendment 1]) 8.2. Platelets greater than 75,000 cells/mm^3 8.3. Creatinine less than 2.0 mg/dL 8.4. Serum calcium less than 12 mg/dL 9. Serum ferritin at least 12 mg/mL and transferrin saturation at least 15% as determined by the prestudy evaluation 10. Stool occult blood (negative) 11. A desire and competence to self-administer the study drug or willing to come to the clinic three days each week for the duration of the study to receive study medication 12. Informed consent was obtained for subjects before enrolment in the study
Exclusion criteria
Exclusion criteria: Subjects meeting any of the following criteria were not to be included in the study: 1. History of any primary non-malignant heamatologic disease 2. Clinically significant disease/dysfunction of the pulmonary, cardiovascular, endocrine, neurological, gastrointestinal, or genitourinary systems not attributable to underlying malignancy and making implementation of the protocol or interpretation of the study results difficult 3. Uncontrolled hypertension (i.e. diastolic Blood Pressure [BP] greater than 100 mmHg) at the prestudy evaluation 4. Evidence of folate or B12 deficiency defined as below the lower standard value for the central laboratory 5. Androgen therapy within two months of randomisation to study medication 6. Known hypersensitivity to erythropoietin 7. Known hypersensitivity to products derived from mammalian cell-culture systems 8. Experimental drug administered or experimental device used within 30 days prior to randomisation to study medication 9. Radiation therapy completed within four weeks before randomisation to study medication or extensive radiation therapy defined as more than 40% of marrow exposed in the radiation field completed within six weeks before randomisation to study medication 10. A malignancy requiring bone marrow transplant or stem cell transplant in the forthcoming 24 weeks (six months) 11. Bone marrow transplant or stem cell transplant recipients 12. Loss of blood requiring Red Blood Cell (RBC) transfusion within the last 30 days 13. Subjects known to be Human Immunodeficiency Virus (HIV) positive 14. Blood (500 ml) or equivalent serum donation during the last three months (as per Amendment 1) 15. Pregnant 16. Breast feeding 17. Treatment with other erythropoietins within the last 12 weeks before randomisation to study medication 18. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol 19. Clinically relevant cardiovascular disease requiring treatment, including but not limited to: 19.1. Myocardial infarction in the preceding six months 19.2. Cardiac arrhythmia 19.3. Unstable angina 20. Current drug abuse 21. Impaired hepatic function, defined as prestudy value for Aspartate Transaminase (AST [SGOT]) or Alanine Transaminase (ALT [SGPT]) exceeding twice the upper limit of normal of the central laboratory values 22. A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study 23. Subjects unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The co-primary efficacy endpoints in this study were the determination of each subject?s change in haemoglobin from baseline to week 12 and the occurrence of red blood cell transfusions during week 5 to 12 (yes/no). The primary analysis was based on the Intent-To Treat (ITT) population. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary efficacy endpoints were: 1. Change in FACT-An fatigue subscale from baseline to week 12 2. Number of RBC transfusions received during weeks 5 - 12 (expressed as a rate per 28 days) 3. Number of RBC units transfused during weeks 5 - 12 (expressed as a rate per 28 days) 4. Change in Haematocrit (Hct) at week 12 when compared to baseline 5. Average Hgb during weeks 5 - 12 6. Rate of change of Hgb from baseline to first treatment interruption or to when a blood transfusion (red cell or whole blood) was first received 7. Average Hct during weeks 5 - 12 8. Rate of change of Hct from baseline to first treatment interruption or to when a blood transfusion (red cell or whole blood) was first received 9. Change in the total FACT-An score from baseline to week 12 10. Change in each non-fatigue subscale from baseline to week 12 | — |
Countries
United States of America
Outcome results
None listed